I happened to notice a new clinical trial is open for previously untreated patients. The facilities include Memorial Sloan Kettering in NYC; Dana Farber in Boston; and Yale Medical Center in New Haven, CT. Here is a brief summary: This is a multi-center, open label, single arm, phase II trial of the oral BRAF inhibitor, vemurafenib, plus obinutuzumab in patients with previously untreated HCL. Below is a link. This doesn't apply to most of us since it is for new patients. But, it might apply to someone who is newly diagnosed and looking for options.
https://www.clinicaltrials.gov/ct2/show ... mia&rank=5
2 posts • Page 1 of 1